Fetcroja (cefiderocol) and Zavicefta (ceftazidime–avibactam) could soon become the first antibiotics to be made available in England as part of an innovative subscription-style payment model that aims to incentivize the development of novel antimicrobials and tackle the problem of antimicrobial resistance (AMR).
The new UK payment model, the first of its kind in the world, will ensure that a fixed annual fee is paid to companies based on the value of their...